NCT01427114View on ClinicalTrials.gov

R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

August 1, 2014

Study Completion Date

January 1, 2021

Conditions
Lymphoma
Interventions
DRUG

rituximab, cyclophosphamide, vincristine, and prednisolone

6 cycles of R-CVP followed by 2 cycles of rituximab

Trial Locations (2)

137-701

Seoul St. Mary's Hospital, Seoul

143-729

KonKuk University Medical Center, Seoul

All Listed Sponsors
collaborator

Seoul St. Mary's Hospital

OTHER

lead

Konkuk University Medical Center

OTHER

NCT01427114 - R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) | Biotech Hunter | Biotech Hunter